CEL-SCI Presents Head & Neck Cancer Data At IDDST Annual Congress In Budapest: Risk Of Death Cut In Half For Patients Treated With Multikine In The Target Population

• Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors
• 73% survival for Multikine vs 45% in the control arm at 5 years
• Statistically significant log rank p = 0.0015
• 5-year risk of death cut in half from 55% to 27%
• Hazard ratio = 0.35 (95% CIs [0.19, 0.66])
• Working to commence FDA confirmatory Registration Study for Multikine

CEL-SCI Corporation (NYSE:CVM) today announced the Company's Chief Scientific Officer, Dr. Eyal Talor, delivered a presentation titled "Neoadjuvant Immunotherapy for Head and Neck Cancer: Low Tumor PD-L1 Expression - IT-MATTERS – RCT" at the International Drug Discovery Science & Technology (IDDST) 20th Annual Congress in Budapest, Hungary on Tuesday, June 18, 2024. Dr. Talor presented during the Cancers/Tumors session which he Chaired along with Dr. Elizabeth Tran of Purdue University.